Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Dec 17, 2014
Insider Transaction Report
Form 4
Claiborne Cary J
Chief Financial Officer
Transactions
- Sale
Class A Common Stock
2014-12-15$12.89/sh−7,100$91,519→ 2,864 total - Sale
Class A Common Stock
2014-12-16$12.91/sh−42,900$553,839→ 2,864 total - Exercise/Conversion
Employee Stock Option (right to buy)
2014-12-16−42,900→ 99,987 totalExercise: $4.07From: 2013-06-04Exp: 2021-10-17→ Class A Common Stock (42,900 underlying) - Exercise/Conversion
Class A Common Stock
2014-12-15$4.07/sh+7,100$28,897→ 9,964 total - Exercise/Conversion
Class A Common Stock
2014-12-16$4.07/sh+42,900$174,603→ 45,764 total - Exercise/Conversion
Employee Stock Option (right to buy)
2014-12-15−7,100→ 142,887 totalExercise: $4.07From: 2013-06-04Exp: 2021-10-17→ Class A Common Stock (7,100 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.05, inclusive. The reporting person undertakes to provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.15, inclusive. The reporting person undertakes to provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.